scholarly journals San Antonio 2019: interesting topics for daily clinical practice in breast cancer

2020 ◽  
Vol 13 (3) ◽  
pp. 349-352
Author(s):  
Arik Galid
Keyword(s):  
Breast Cancer ◽  
Clinical Practice ◽  
Hormone Replacement Therapy ◽  
Hormone Receptor ◽  
San Antonio ◽  
Hormone Replacement ◽  
Daily Practice ◽  
Hormone Receptor Positive ◽  
Treat Breast Cancer ◽  
Positive Breast Cancer

Summary The San Antonio Breast Cancer Summit is one of the most important meetings worldwide for physicians who treat breast cancer. As traveling there is always somewhat of an adventure due to the distance and the time of the year (winter) and access is not easy for all physicians, the goal of this article is to provide an overview of the presentations dealing with hormone-receptor-positive breast cancer, capecitabine, prevention, and hormone replacement therapy. Data and results should positively influence daily practice.

Safety of using hormone replacement therapy in breast cancer survivors: A systematic review and metanalysis.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 12067-12067
Author(s):  
Francesca Poggio ◽  
Lucia Del Mastro ◽  
Marco Bruzzone ◽  
Marcello Ceppi ◽  
Maria Grazia Razeti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Hormone Replacement Therapy ◽  
Hormone Receptor ◽  
Hormone Replacement ◽  
Disease Recurrence ◽  
Hormone Receptor Status ◽  
Risk Of Recurrence ◽  
Hormone Receptor Positive ◽  
Risk Of Disease

12067 Background: Improvements in breast cancer (BC) care have led to increased survival of patients; hence, more attention to long-term treatment-related adverse events and quality of life (QoL) is required. Symptoms of spontaneous and treatment-induced menopause significantly affect the QoL and adherence to endocrine therapy among BC survivors, with potential negative implications on outcome. Use of systemic hormone replacement therapy (HRT) to mitigate menopause-associated symptoms is not recommended to reduce the burden of these side effects being historically associated with an increased risk of disease recurrence. This systematic review and metanalysis aimed to estimate the effect of HRT on risk of disease recurrence in BC survivors. Methods: A systematic search of Pubmed and Embase libraries up to January 15, 2021, was conducted in order to identify randomized controlled trials (RCTs) investigating the risk of disease recurrence with the use of HRT in BC survivors. We used the random-effect model to calculate the overall risk of recurrence, reported as pooled hazard ratio (HR) with 95% confidence intervals (CI). Moreover, we performed a subgroup analysis to estimate the risk of recurrence according to hormone receptor status. The Higgins I2 index was computed to assess the heterogeneity between studies. The likelihood of publication bias was assessed by Egger’s test. Results: Four RCTs were found and three were included in the metanalysis (n = 3.973 patients); one study (n = 100 patients) was excluded due to the impossibility to extract the HR for disease recurrence. Overall, 1.990 patients were randomized to receive HRT (estrogen-progesteron combination or tibolone), while 1.983 patients were included in control groups (placebo or no HRT). As compared to control group, HRT significantly increased the risk of BC recurrence (HR 1.49, 95% CI 1.15-1.93, p = 0.002). The heterogeneity between the studies was low (39%, p = 0.194), and no publication bias was found ( p = 0.537). Two studies reported the HR according to hormone receptor status. At the subgroups analysis, the risk of BC recurrence with the use of HRT was significantly increased in hormone receptor-positive patients (HR 1.8, 95% CI 1.15-2.82, p = 0.010) but not in those with hormone receptor-negative tumors (HR 1.25, 95% CI 0.83-1.88, p = 0.290). Conclusions: Use of HRT significantly increases the risk of recurrence in BC survivors, particularly in those with hormone receptor-positive disease. Therefore, this approach remains contraindicated in this setting. Alternative interventions to mitigate menopause-related symptoms should be proposed to these patients.

Options for Endocrine-Refractory, Hormone Receptor–Positive Breast Cancer: Which Target and When?

2021 ◽  
Author(s):  
Virginia F. Borges
Keyword(s):  
Breast Cancer ◽  
Clinical Practice ◽  
Hormone Receptor ◽  
Relevant Literature ◽  
Clinical Context ◽  
Case Presentation ◽  
Hormone Receptor Positive ◽  
Management Approaches ◽  
Grand Rounds ◽  
Positive Breast Cancer

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.

scholarly journals HOXB7 siRNA delivered by hybrid nanoparticles and the co-therapy with tamoxifen: promising strategy against hormone receptor positive breast cancer

2020 ◽  
Author(s):  
Frederico Pittella ◽  
Ana Beatriz Valle ◽  
Ana Cristina Gualberto ◽  
Kézia Ferreira ◽  
Tânia Pasa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Hybrid Nanoparticles ◽  
Hormone Receptor Positive ◽  
Promising Strategy ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document